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The fatigue prevalence in breast cancer survivors is high during the endocrine treatment. However, there are few evidence-based
interventions to manage this symptom. The aim of this study was to investigate the eﬀectiveness of spore powder of Ganoderma
lucidum for cancer-related fatigue in breast cancer patients undergoing endocrine therapy. Spore powder of Ganoderma lucidum is
a kind of Basidiomycete which is a widely used traditional medicine in China. 48 breast cancer patients with cancer-related fatigue
undergoing endocrine therapy were randomized into the experimental or control group. FACT-F, HADS, and EORTC QLQ-C30
questionnaires data were collected at baseline and 4 weeks after treatment. The concentrations of TNF-α, IL-6, and liver-kidney
functions were measured before and after intervention. The experimental group showed statistically signiﬁcant improvements in
the domains of physical well-being and fatigue subscale after intervention. These patients also reported less anxiety and depression
and better quality of life. Immune markers of CRF were signiﬁcantly lower and no serious adverse eﬀects occurred during the
study. This pilot study suggests that spore powder of Ganoderma lucidum may have beneﬁcial eﬀects on cancer-related fatigue and
quality of life in breast cancer patients undergoing endocrine therapy without any signiﬁcant adverse eﬀect.
1.Introduction
Breast cancer was the most common cancer to aﬀect women
[1]. Because of advances in diagnosis and medical treatment
of breast cancer, the number of survivors has grown rapidly.
These survivors have some conditions and symptoms that
can aﬀect not only the quality of their lives, but also their
overall survival time [2–4]. One of symptoms which the
breast cancer patients often reported is fatigue [5]. Cancer-
related fatigue (CRF) is a distressing, persistent, and sub-
jective sense of physical, emotional, and cognitive tiredness
related to cancer or cancer treatment that is not proportional
to recent activity and interferes with normal functioning [6].
Studies indicate that CRF in breast cancer patients undergo-
ing endocrine therapy could be mediated by the endocrine
sequelae of breast cancer treatment, including menstrual dis-
order, the induction of premature menopause due to ovarian
toxicity caused by chemotherapy, radiotherapy, and the side
eﬀects of adjuvant endocrine treatment [7–9]. Other poten-
tialfactorstoconsideraresomephysicaldistress,suchasane-
mia, coronary artery disease, metabolic abnormalities, and
emotional distress including anxiety and depression [10, 11].
The pathophysiologic mechanisms of fatigue in breast
cancer patients are not completely understood. Barsevick
et al. ﬁnd that there are many potential mechanisms
which can result in CRF. These mechanisms include that
cytokine disorder, 5-hydroxy tryptophan (5-HT) neurotrans-
mitter dysregulation, abnormal hypothalamic-pituitarya-
drenal (HPA) axis function, and unusual metabolism of ade-
nosine tri-phosphate (ATP) and muscle. Breast cancer sur-
vivors with persistent and gradually aggravating fatigue after
treatment had increased levels of immune markers related
with proinﬂammatory cytokine such as interleukin (IL-6)
and tumor necrosis factor (TNF-α)a c t i v i t y[ 13–15].
Despite the prevalence of cancer-related fatigue, there are
few evidence-based interventions to manage this symptom.2 Evidence-Based Complementary and Alternative Medicine
Some researches have examined exercise or psychological
treatmentsforcancer-relatedfatigue,andtheseinterventions
have been shown to reduce fatigue levels and have the evi-
dence support [16–18]. However, survivors with fatigue may
be unwilling or unable to go to exercise. Even some breast
cancer patients said the more they exercise, the more fatigue
they feel. There is also no agreement on the best drug treat-
ment for CRF. The only speciﬁc drug recommendation
in NCCN is psychostimulant methylphenidate. However, it
should be given only under expert supervision and had a po-
tential risk of longer-term addiction [19–21].
Traditional Chinese medicine can regulate the balance of
the body and have fewer adverse reactions if its application
is reasonable. Spore powder of Ganoderma lucidum (G. lu-
cidum) is a kind of Basidiomycete which is a widely used
traditional medicine in China [22]. Modern research veriﬁed
that spore powder of G. lucidum has multiple functions,
such as blocking histamine release and inhibiting an over-
stimulated immune system, and has an eﬀect on regulating
cellular and humoral immunity [23–25]. Spore powder of G.
lucidum has many eﬀective components including bioactive
compoundslikepolysaccharides,triterpenoids,alkaloids,en-
zymes, and proteins [26]. Some researchers ﬁnd that the tri-
terpenoids from G. lucidum suppressed the secretion of in-
ﬂammatory cytokine TNF-α and interleukin-6 and inﬂam-
matory mediator nitric oxide (NO) and prostaglandin E2
(PGE2) from lipopolysaccharide-(LPS-) stimulated murine
RAW264.7 cells [27].
On the basis on these research results, spore powder of G.
lucidum has been suggested as an alternative therapy to con-
trol the cancer-related fatigue. The objective of the present
study was to evaluate whether spore powder of G. lucidum
has beneﬁcial eﬀects on fatigue and overall quality of life in
patients with breast cancer undergoing endocrine therapy.
2. Methods
2.1. Design. The study was performed as a randomized con-
trolled trial comparing an experimental group with control
group. Patients in the experimental group were administered
with spore powder of G. lucidum 1000mg three times a day
for 4 weeks (From Beijing Great Wall Pharmaceutical Fac-
tory, Batch number B20050008). The control group received
placebofor4weeks.Atbaselineandtheendof4weeks,func-
tionalassessmentofcancertherapy-fatigue(FACT-F),hospi-
tal anxiety and depression scale (HADS), EORTC quality-of-
life questionnaires (QLQ-C30) data were collected; the con-
centrations of TNF-α, IL-6, and liver-kidney function were
measured.
2.2. Participants. The study protocol and all procedures
were reviewed and approved by The Institutional Review
Board of The Third Aﬃliated Hospital of Harbin Medical
University. All participants were provided written informed
consent. These patients were received endocrine therapy for
breast cancer at the Third Aﬃliated Hospital of Harbin
Medical University, Harbin, China, between June, 2009 and
September, 2010. All patients answered one question each
about fatigue and energy. Fatigue was measured with a sin-
gle item “How much fatigue have you had during the past
4 weeks?” with possible values from 0 (“A great deal of fa-
tigue”) to 10 (“No fatigue at all”). Energy was measured
with a single item, “How much energy have you had dur-
ing the past 4 weeks?” with possible values from 0 (“No
energyatall”)to10(“Agreatdealofenergy”).Thecaseswere
conﬁrmed by a pathological examination; estrogen recep-
tor (ER) and progesterone receptor (PR) statuses were evalu-
ated by standard immunohistochemistry. All patients were
ER-positive and PR-positive or PR-negative. The eligibility
criteria for study participation were as follows: (a) at least
18 years of age, (b) no documented or observable psychi-
atric or neurological disorders that would interfere with
participation, (c) women diagnosed with stage I-IIIA breast
cancer, (d) no history of another cancer, (e) no other chron-
ic or life-threatening diseases in which fatigue is a prominent
symptom (e.g., multiple sclerosis, rheumatoid arthritis, ﬁ-
bromyalgia, or chronic fatigue syndrome), (f) previous sur-
gical treatment for breast cancer, (g) completed or under-
going endocrine therapy, (h) endocrine therapy for more
than six months, and (i) provision of written informed con-
sent. The exclusion criteria applied to patients who (a) had
anemia,deﬁnedashemoglobinlevel<9g/dLorpatientswith
platelets <80000/mL, (b) showed levels of abnormal range in
serum alanine transaminase (ALT), aspartic acid transami-
nase (AST), blood urea nitrogen (BUN), or creatinine level,
(c) had thyroid disorder with abnormal thyroid stimulating
hormone and free T4 level.
2.3. Questionnaires Procedures
FACT-F (Functional Assessment of Cancer Therapy: Fatigue).
It includes 40 Likert-type items in four scales that assess
quality of life in the domains of physical well-being (seven
items); social/family well-being (seven items); emotional
well-being (six items); functional well-being (seven items);
and 13 items in one scale that assesses fatigue. The patients
were asked to answer to each item with a score from 0 (not at
a l l )t o4( v e r ym u c h )[ 28, 29].
HADS (The Hospital Anxiety and Depression Scale). It con-
sists of two subscales: a seven-item anxiety subscale (HADS-
A)andaseven-itemdepressionsubscale(HADS-D).Thepos-
sible scores of both HADS-A and HADS-D range from 0 to
21. A normal value ranges from 0 to 7; a mild disorder ranges
from 8 to 10; while scores of 11 or more are considered to be
moderate to severe disorder [30]. Some previous studies in-
dicated that the HADS is a valid questionnaire to measure
psychological morbidity of Iranian breast cancer patients
[31].
EORTC QLQ-C30 (European Organisation for Research and
Treatment of Cancer Core Quality of Life Questionnaire C30).
It consists of 30 items that reﬂect the multidimensionality
of patients’ quality-of-life construct [32]. This questionnaire
incorporates ﬁve functional scales (physical, role, cognitive,
emotional, and social), three symptom scales (fatigue, pain,
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insomnia, loss of appetite, constipation, diarrhea, and ﬁnan-
cial troubles), each item with a score from 1 (not at all) to 4
(very much).It also includes a global health and quality-of-
life scale, each item with a score from 1 (not at all) to 7 (very
much) [33].
2.4. Markers of Fatigue. Blood samples were collected during
before and after treatment and were centrifuged to allow
serum collection. Serum samples were stored at −80◦C. En-
zyme-linked immunosorbent assays (ELISA) were used to
determine the concentrations of TNF-α and IL-6.
2.5. Safety and Toxicity. Tests for safety and toxicity included
the renal function test (sodium, potassium, and urea crea-
tinine) and liver function test (total protein, albumin, total
bilirubin, alkaline phosphate, and alanine transaminase) at
baseline and end of the administration period (week 4). The
adverse eﬀect was assessed using the National Cancer Insti-
tute Common Toxicity Criteria (NCICTC, version 2.0) scale.
2.6. Data Analysis. All analyses were based on data obtained
from the aforementioned questionnaires, which were certi-
ﬁed by clinical oncologists and by the participants them-
selves. Demographic variables were analyzed by descriptive
statistics to evaluate the clinical and characteristics of the
studied samples. T-test and linear regression analyses were
used. Comparison-of-quality of life scores at diﬀerent phases
of treatment were performed using analysis of variance tests
for paired samples. Linear regression models were created
using the concentrations of TNF-α, IL-6 as the dependent
variables, and the variances of cancer-related fatigue as
independent variables. Values are expressed as the mean ±
standarddeviation(mean ±SD)unlessstatedotherwise,and
diﬀerences were considered statistically signiﬁcant at P<
0.05. The statistical software SPSS for Windows version 15.0
was used for all statistical analyses.
3. Result
3.1. Baseline Characteristics of the Participants. From June
2009 and September 2010, 48 breast cancer patients with
cancer-related fatigue undergoing endocrine therapy were
randomized into an experimental or a control group. There
are 25 patients in an experimental group and 23 in control
group. Huang et al. [9] found that BMI, clinical stage,
menopausal status, duration of endocrine therapy, physical
activity, and diet are associated with fatigue in breast cancer
patients undergoing endocrine therapy. The baseline char-
acteristics were not signiﬁcantly diﬀerent between the two
groups. Baseline demographic and clinical characteristics are
described in Table 1.
3.2. Outcome Measures
3.2.1. Intervention Eﬀects on Fatigue. Compared with control
group, the majority changes of experimental group in FACT-
Fwereobservedinthedomainsofphysicalwell-being(mean,
24.62) and fatigue subscale (mean, 46.78) (P<0.01 and
P<0.01, resp.). The emotional (mean, 21.49) and func-
tional well-being (mean, 22.87) of patients improve after
intervention (P<0.05 and P<0.05, resp.). The total score
of FACT-F was 120.31 (mean) at baseline, and it increased to
141.09 (mean) at the end of 4 weeks in experimental group
(P<0.01). No signiﬁcant diﬀerence was between at baseline
a n da tt h ee n do f4w e e k si nc o n t r o lg r o u p( Table 2).
3.2.2. Intervention Eﬀects on Anxiety and Depression. The
signiﬁcant diﬀerence in scores of depression assessment
betweenexperimentalgroupandcontrolgroupwasobserved
at end of 4 weeks (P<0.01). The mean scores of anxiety
(4.1) and depression (3.1) assessments in the HADS after
treatment were lower than the scores before intervention.
Depression of patients in control group at baseline and the
end of 4 week had no signiﬁcant diﬀerence (Table 3).
3.2.3. Intervention Eﬀects on Quality of Life. In functioning
and global quality-of-life scale in EORTC QLQ-C30, the
scoresofemotionalfunctioningandcognitivefunctioninthe
experimental group (the respective mean scores were 79.5
and 75.1) were higher than the outcomes in control group
(P<0.05). The domains of physical function (78.2) and
global quality of life (68.9) were all signiﬁcantly improved
after 4-week spore powder of G. lucidum treatment (P<
0.01).Nosigniﬁcantchangewasfoundinthedomainsofrole
functioningandsocialfunctioning(Table 4).Comparedwith
control group, the fatigue, sleep disturbance, and appetite
loss of patients in experimental group were improved
according to the outcomes of the EORTC QLQ-C30 (P<
0.01, P<0.01 and P<0.05, resp.) (Table 5).
3.3. The Concentration of TNF-α and IL-6. Analysis of the
relationship between the concentration of TNF-α and the
variances of cancer-related fatigue using linear regression
found that they have linear correlation. And the con-
centration of IL-6 has linear correlation with the vari-
ances of cancer-related fatigue. In an exploratory analysis
of proinﬂammatory cytokines, markers of cancer-related
fatigue, the mean serum concentrations of TNF-α pre- and
posttreatmentinexperimentalgroupwere128.70pg/mLand
71.89pg/mL. The level of TNF-α in serum was signiﬁcantly
lower (P<0.01). The mean serum concentrations of
IL-6 pre- and posttreatment in experimental group were
62.43pg/mLand37.62pg/mL.ThelevelofIL-6inserumwas
lower (P<0.05) (Figures 1 and 2).
4.Toxicity
No serious adverse eﬀects occurred during the study. Only
mild discomforts were recorded, and these are shown in
Table 6. The two most common discomforts were dizziness
(16.0%) and dry mouth (12.0%).
There was no signiﬁcant change in diﬀerent parameters
of the renal function test (sodium, potassium, and urea
creatinine) and liver function test (total protein, albumin,
total bilirubin, alkaline phosphate, and alanine transami-
nase) during the study period. All these parameters were
generally within the normal range both before and after
study.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Demographics of patients in each group.
Experimental group (n = 25) Control group (n = 23) P-value
(1) age (year)
mean (SD) 51.3 (9.8) 53.2 (8.7) P>0.1
(2) Body mass index (kg/m2)
mean (SD) 22.9 (3.8) 23.2 (3.5) P>0.1
(3) Menopausal status n (%) P>0.05
Pre-menopause 10 (40.0%) 12 (52.1%)
Post-menopause 15 (60.0%) 11 (47.9%)
(4) Clinical stage n (%) P>0.05
Stage I 8 (32.0%) 7 (30.4%)
Stage II 10 (40.0%) 9 (39.2%)
Stage IIIA 7 (28.0%) 7 (30.4%)
(5) Treatment n (%) P>0.05
Surgery + endocrine therapy 4 (16.0%) 3 (13.1%)
Surgery + radiation + endocrine therapy 4 (16.0%) 4 (17.3%)
Surgery + chemotherapy + endocrine
Therapy 11 (44.0%) 10 (43.5%)
Surgery + chemotherapy + radiation + endocrine therapy 6 (24.0%) 6 (26.1%)
(6) Duration of endocrine therapy n (%) P>0.05
>6 Months to 3 years 15 (60.0%) 13 (56.5%)
>3 years to 5 years 10 (40.0%) 10 (43.5%)
(7) Physical Activity n (%) P>0.05
MHW < 3.3 2 (8.0%) 1 (4.3%)
3.3 ≤ MHW < 10.0 7 (28.0%) 10 (43.5%)
10.0 ≤ MHW < 20.0 12 (48.0%) 9 (39.1%)
MHW ≥ 20.0 4 (16.0%) 3 (13.1%)
(8) Diet n (%) P>0.05
0 3 (12.0%) 2 (8.6%)
1∼2 7 (28.0%) 6 (26.1%)
3∼4 8 (32.0%) 9 (39. 2%)
5 7 (28.0%) 6 (26.1%)
5. Discussion
This pilot study suggests that spore powder of G. lucidum
may have beneﬁcial eﬀects on cancer-related fatigue and
quality of life in breast cancer patients undergoing endocrine
therapy without any signiﬁcant adverse eﬀect. The patients
who received with spore powder of G. lucidum for 4 weeks
can decrease degree of fatigue. To our knowledge, this is the
ﬁrst detailed study of adherence to an individualized tradi-
tional Chinese medicine intervention targeting generalized
cancer-related fatigue during endocrine therapy.
Endocrinetherapywasproposedasatreatmentforbreast
cancer in patients who were with estrogen and/or pro-
gesterone receptor-positive tumors. Studies indicate that the
fatigue prevalence in patients with breast cancer is high dur-
ing the endocrine treatment [34]. Fatigue in young breast
cancer survivors may experience premature menopause due
toestrogendeprivationtreatment,thustheyexperiencemen-
opause-related fatigue more earlier in life than those natural
menopausal people [35, 36]. Despite exercise or psycholog-
ical treatments and some medicines used to improve the
cancer-related fatigue, these methods may have some short-
comings and deﬁciencies.
In this pilot clinical trial, we apply traditional Chinese
medicine spore powder of G. lucidum to improve cancer-
related fatigue. In this study, FACT-F was used to assessing
of global fatigue level, and HADS was used to evaluate the
anxiety and depression level; quality of life was assessed with
EORTC QLQ-C30. From the results of FACT-F, we can ﬁnd
thatthescoresofphysicalwell-beingandfatiguescalechange
quickly after interventions. These ﬁndings are particularly
encouraging given that study participants had experienced
fatigue for several years before trial onset. However, the score
of the social/family well-being was no signiﬁcant diﬀerence
between before and after interventions. The results of
EORTC QLQ-C30 in this study showed signiﬁcant improve-
ments in physical functioning, emotional functioning, and
cognitive functioning of patients. These ﬁndings suggest that
the intervention may have beneﬁcial eﬀect on strength in
addition to subjective symptoms. Meanwhile, the symptoms
ofsleepdisturbanceandappetitelossdecreasedwithimprov-
ing cancer-related fatigue. Anxiety and depression scoresEvidence-Based Complementary and Alternative Medicine 5
Table 2: FACT-F scores for experimental group and control group.
Subscal (range of scores) Experimental
group (n = 25)
Control group
(n = 23)
Physical (0–28)
Week 0 20.35 ±4.07 19.43 ±4.19
Week 4 24.62 ± 3.27∗∗## 20.65 ±3.97
Social/family (0–28)
Week 0 21.35 ±3.91 20.89 ±3.91
Week 4 22.37 ±3.61 21.12 ±4.07
Emotional (0–24)
Week 0 17.61 ±4.00 16.73 ±3.87
Week 4 21.49 ±2.21∗# 17.99 ±2.07
Functional (0–28)
Week 0 17.87 ±4.93 17.35 ±4.87
Week 4 22.87 ±5.13∗# 18.29 ±3.79
Fatigue subscale (0–52)
Week 0 39.76 ±5.10 40.35 ±6.10
Week 4 46.78 ± 5.07∗∗## 40.92 ±5.62
Total (0–160)
Week 0 120.31 ±20.15 119.65 ±18.99
Week 4 141.09 ± 17.23∗∗## 121.01 ±19.13
∗P<0.05 versus week 0 of experimental group.
∗∗P<0.01 versus week 0 of experimental group.
#P<0.05 versus week 4 of control group.
##P<0.01 versus week 4 of control group.
Table 3: HAD scores for experimental group and control group.
Subscale Experimental group
(n = 25)
Control group
(n = 23)
Anxiety
Week 0 6.3 ±3.26 .5 ±3.4
Week 4 4.1 ±2.9∗# 6.1 ±3.2
Depression
Week 0 4.9 ±3.84 .8 ±3.1
Week 4 3.1 ±2.8∗∗## 4.6 ±2.9
Total
Week 0 10.9 ±4.11 0 .8 ±3.9
Week 4 7.1 ±3.1∗∗## 9.8 ±3.4
∗P<0.05 versus week 0 of experimental group.
∗∗P<0.01 versus week 0 of experimental group.
#P<0.05 versus week 4 of control group.
##P<0.01 versus week 4 of control group.
declined signiﬁcantly over the study, indicating a possible
improvement in anxiety and depression. One explanation
for the improvement in depression is that with less fatigue
and more energy, these breast cancer survivors were able to
do some activities that they previously had given up. These
activities brought pleasure into their lives.
The pharmacological eﬀect of spore powder of G. lucid-
um is based on their powerful immune-modulating action
and immune potential capability. The active elements of it
downregulated the expression of iNOS and COX-2, sup-
Table 4: Patients’ functioning and global quality of life scores as
measured by the EORTC QLQ-C30.
Subscale Experimental group
(n = 25)
Control group
(n = 23)
Functional scales
Physical functioning
Week 0 63.7 ±25.9 64.0 ±27.1
Week 4 78.2 ± 26.1∗∗## 64.5 ±28.7
Role functioning
Week 0 65.2 ±33.6 68.1 ±31.2
Week 4 79.1 ±31.1 69.3 ±32.4
Emotional
functioning
Week 0 61.3 ±30.2 62.2 ±32.5
Week 4 79.5 ± 31.5∗∗## 64.3 ±31.8
Social Functioning
Week 0 72.4 ±29.1 74.3 ±28.6
Week 4 76.1 ±26.8 75.5 ±27.9
Cognitive functioning
Week 0 65.6 ±24.3 66.4 ±23.2
Week 4 75.1 ±26.5∗# 68.3 ±26.3
Global Quality of Life
Week 0 55.8 ±22.9 56.6 ±23.0
Week 4 68.9 ± 21.4∗∗## 57.7 ±24.2
∗P<0.05 versus week 0 of experimental group.
∗∗P<0.01 versus week 0 of experimental group.
#P<0.05 versus week 4 of control group.
##P<0.01 versus week 4 of control group.
pressed the release of TNF-α and IL-6, and suppressed the
LPS-dependent activation of NF-κB in RAW264.7 cells [27,
37]. From the ELISA consequence of cytokines as markers
of cancer-related fatigue, the concentrations of TNF-α and
IL-6 after treatment were signiﬁcant lower than these before
treatment.
In this 4-week study, spore powder of G. lucidum was
well tolerated. No serious adverse eﬀects occurred during the
study. Most side eﬀects were mild dizziness. At the end of 4
weeks, the levels of ALT, AST, BUN, and creatinine were no
signiﬁcant diﬀerence than these at baseline in statistics.
Although these results are promising, the study has limi-
tations that render the ﬁndings preliminary. The ﬁrst is the
small sample size; only 48 women participated in the inter-
vention. Therefore, a sampling bias does exist. In addition, it
is possible that nonspeciﬁc aspects of the intervention (e.g.,
social support) may have inﬂuenced fatigue scores.
Despite these limitations, our data suggest that spore
powder of G. lucidum is a well-tolerated option for the treat-
ment of cancer-related fatigue. In addition, the improve-
ments in emotional functioning seen in our study suggest
that it has a place for the treatment of depression in patients
whose treatment with traditional antidepressants impracti-
cal. More rigorous trials are needed to conﬁrm the eﬃca-
cy of Spore of G. lucidum.6 Evidence-Based Complementary and Alternative Medicine
Table 5: Patients’ symptom scores on the EORTC QLQ-C30.
Symptom scales Experimental group
(n = 25)
Control group
(n = 23)
Fatigue
Week 0 43.7 ±17.9 42.3 ±15.7
Week 4 31.1 ±18.1∗∗## 40.2 ±16.8
Pain
Week 0 32.4 ±12.7 31.3 ±13.6
Week 4 29.3 ±14.6 30.7 ±17.3
Sleep disturbance
Week 0 56.5 ±21.8 55.8 ±22.6
Week 4 42.3 ±26.2∗∗## 53.9 ±24.8
Appetite loss
Week 0 32.5 ±19.3 32.3 ±17.4
Week 4 24.3 ±18.4∗# 30.3 ±16.5
Constipation
Week 0 31.1 ±11.4 32.5 ±12.8
Week 4 28.2 ±13.3 30.6 ±14.7
Diarrhea
Week 0 12.9 ±10.9 12.7 ±10.5
Week 4 11.8 ±8.8 10.6 ±9.6
∗P<0.05 versus week 0 of experimental group.
∗∗P<0.01 versus week 0 of experimental group.
#P<0.05 versus week 4 of control group.
##P<0.01 versus week 4 of control group.
Table 6: Mild adverse events of patients in Experimental Group.
Adverse events Cases (%)
Dizziness 4 (16.0%)
Dry mouth 3 (12.0%)
Diarrhea 2 (8.6%)
Stomach discomfort 2 (8.6%)
Nausea 2 (8.6%)
Epistaxis 1 (4.0%)
Sore throat 1 (4.0%)
6. Conclusion
Cancer-related fatigue and poor quality of life are serious
problems that signiﬁcantly aﬀect the morbidity of breast
cancer patients. Spore of G. lucidum may oﬀer a useful com-
plementary treatment that can improve the situations in the
experimental group. This pilot clinical trial is the ﬁrst step to
explore the eﬃcacy of herbal therapy on fatigue and quality
oflifeinbreastcancerpatients.Resultsfromthestudiescould
provide evidence for eﬃcacy and might be used to design
more future comprehensive studies.
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Figure 1: The concentrations of TNF-α in experimental group and
control group at baseline and 4 week.
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Figure 2: The concentrations of IL-6 in experimental group and
control group at baseline and 4 week.
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